Cantor Fitzgerald Comments on Organogenesis FY2024 Earnings

Organogenesis Holdings Inc. (NASDAQ:ORGO) – Research analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for shares of Organogenesis in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings of ($0.06) per share for the year, up from their prior forecast of ($0.17). The consensus estimate for Organogenesis’ current full-year earnings is ($0.12) per share.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The company had revenue of $115.18 million during the quarter, compared to analyst estimates of $109.59 million. During the same period in the previous year, the business posted $0.02 earnings per share.

Organogenesis Trading Up 2.1 %

Shares of ORGO stock opened at $3.94 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.42. The company has a market cap of $522.35 million, a price-to-earnings ratio of -64.33 and a beta of 1.60. Organogenesis has a 1 year low of $2.16 and a 1 year high of $4.70. The firm has a fifty day moving average price of $3.02 and a 200-day moving average price of $2.83.

Institutional Trading of Organogenesis

Hedge funds have recently bought and sold shares of the stock. Captrust Financial Advisors bought a new position in shares of Organogenesis in the third quarter worth about $36,000. Pallas Capital Advisors LLC bought a new stake in Organogenesis during the 2nd quarter worth approximately $38,000. Delap Wealth Advisory LLC purchased a new position in Organogenesis during the second quarter valued at approximately $40,000. Intech Investment Management LLC bought a new position in shares of Organogenesis in the third quarter worth approximately $43,000. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Organogenesis by 4,989.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after purchasing an additional 15,369 shares during the period. Institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.